41 related articles for article (PubMed ID: 10388116)
1. Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.
Kanbayashi Y; Ishikawa T; Kanazawa M; Nakajima Y; Kawano R; Tabuchi Y; Yoshioka T; Ihara N; Hosokawa T; Takayama K; Shikata K; Taguchi T
Med Oncol; 2018 Mar; 35(4):55. PubMed ID: 29549536
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin for cancer-associated malignant anemia: A meta-analysis.
Zhao F; Wang Y; Liu L; Bian M
Mol Clin Oncol; 2017 Jun; 6(6):925-930. PubMed ID: 28588792
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study.
Abdel-Razeq H; Abbasi S; Saadi I; Jaber R; Abdelelah H
Drug Des Devel Ther; 2013; 7():939-44. PubMed ID: 24039403
[TBL] [Abstract][Full Text] [Related]
4. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Peterson ME
Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
[TBL] [Abstract][Full Text] [Related]
5. Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents.
Karlsson T
ISRN Hematol; 2011; 2011():108397. PubMed ID: 22111015
[TBL] [Abstract][Full Text] [Related]
6. Supportive care for patients with early breast cancer.
García-Estévez L; Tusquets I; Alvarez I; Rodríguez C; Fernández Y; Seguí MA; García-Mata J; Lluch A
Clin Transl Oncol; 2010 Jan; 12(1):32-42. PubMed ID: 20080469
[TBL] [Abstract][Full Text] [Related]
7. The role of iron supplementation during epoietin treatment for cancer-related anemia.
Hedenus M; Birgegård G
Med Oncol; 2009; 26(1):105-15. PubMed ID: 18473194
[TBL] [Abstract][Full Text] [Related]
8. Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?
Henry DH
Oncologist; 1998; 3(4):275-278. PubMed ID: 10388116
[TBL] [Abstract][Full Text] [Related]
9. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
Glaspy J; Cavill I
Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
11. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
12. Managing erythropoietin hyporesponsiveness.
Kwack C; Balakrishnan VS
Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
[TBL] [Abstract][Full Text] [Related]
13. Management of renal anemia.
Peco-Antic A
Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
